



MUCOSAL DISEASES (ORAL, ANOGENITAL), EXTERNAL EYE DISEASE

COMPLEMENTARY ROLE OF AN OINTMENT IN COMMON GENITAL DISEASES: IMPACT ON TREATMENT AND QUALITY OF LIFE

C De Belilovsky⁽¹⁾ - Jm Bohbot⁽²⁾

Institut Alfred Fournier, Dermatology, Paris, France⁽¹⁾ - Institut Alfred Fournier, Andrology, Paris, France⁽²⁾

Introduction: Topical steroids (TS) applied for lichen sclerosus (LS) and psoriasis may not totally relieve patients and may affect skin barrier function. Liquid nitrogen (LN) and/or imiquimod prescribed for condyloma acuminata (CA) often damage the epithelium. Tolerance of any applied substance on genital skin may be poor.

Objectives: The study goals were to assess the effects of an ointment added to most common genital disease treatments. The ointment was used with TS for symptomatic patients affected by LS and psoriasis; effects on treatment response were evaluated. The ointment was used with LN and/or imiquimod for CA treatment; effects on side effects were evaluated. The ointment was also used with multidisciplinary treatment for vulvodynia; tolerance was evaluated.

Methods: One-hundred of the 125 enrolled patients completed the study (81 women, 19 men). Twenty-six patients had symptomatic LS and six had symptomatic psoriasis using maintenance TS treatment. Fifty-two patients had CA treatment using LN and/or imiquimod. Sixteen patients had vulvodynia. The tested ointment was applied once to twice daily during the observation period (two visits). The primary efficacy endpoints were a mean statistically significant reduction in subjective and objective scores and a good tolerance. The Dermatitis Life Quality Index (DLQI) was used to evaluate LS and psoriasis. Auto-evaluation questionnaires were completed by all patients.

Results: There were statistically significant reductions in global symptom and clinical scores (LS, -80.61% and -59.20%, respectively; psoriasis, -82.88% and -82.80%, respectively). The DLQI decreased by 40.17% for LS and 76.92% for psoriasis. Use of ointment resulted in low post-treatment scores for CA (global symptom, clinical scores at T1: 1.92 (maximum 50), 2.46 (maximum 24), respectively). Tolerance was good for all except two (one CA, one vulvodynia) patients.

Conclusion: Our results indicated the complementary effects of an ointment added to treatments for LS, psoriasis, CA, and vulvodynia.

